We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Dalton Announces Manufacturing and Development Agreement with RLPC

News   Jul 16, 2015

 
Dalton Announces Manufacturing and Development Agreement with RLPC
 
 
Advertisement
 

RELATED ARTICLES

Head and Neck Cancer: Mutant HRAS Is a Key Cancer-Driving Oncogene

News

Researchers report that an investigational drug called tipifarnib shows promise in treating head and neck squamous cell carcinoma tumors with mutations in the HRAS gene.

READ MORE

Potential New Treatment Tactic for Acute Myeloid Leukemia

News

Researchers demonstrate that factors produced by bone marrow support cells allow leukemia cells to survive treatment with quizartinib. When quizartinib was combined with another tyrosine kinase inhibitor called dasatinib the alternative survival pathways were shut down, leading to more effective leukemia cell death.

READ MORE

Expert Panel Makes Weak Recommendation for Use of Remdesivir To Treat Severe COVID-19

News

International experts have made a weak recommendation for the use of remdesivir in patients with severe COVID-19, advising continuation of patient enrolment for ongoing clinical trials of remdesivir to enable the collection of additional data.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE